CA2322790C - Derives de granulatimide utilises dans le traitement du cancer - Google Patents

Derives de granulatimide utilises dans le traitement du cancer Download PDF

Info

Publication number
CA2322790C
CA2322790C CA002322790A CA2322790A CA2322790C CA 2322790 C CA2322790 C CA 2322790C CA 002322790 A CA002322790 A CA 002322790A CA 2322790 A CA2322790 A CA 2322790A CA 2322790 C CA2322790 C CA 2322790C
Authority
CA
Canada
Prior art keywords
compound
group
cells
compounds
granulatimide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002322790A
Other languages
English (en)
Other versions
CA2322790A1 (fr
Inventor
Raymond J. Andersen
Michel Roberge
Jasbinder Sanghera
Danny Leung
Roberto G.S. Berlinck
Robert Britton
Edward Piers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA 2232074 external-priority patent/CA2232074A1/fr
Priority claimed from CA002245029A external-priority patent/CA2245029A1/fr
Application filed by University of British Columbia filed Critical University of British Columbia
Priority to CA002322790A priority Critical patent/CA2322790C/fr
Priority claimed from PCT/CA1999/000224 external-priority patent/WO1999047522A1/fr
Publication of CA2322790A1 publication Critical patent/CA2322790A1/fr
Application granted granted Critical
Publication of CA2322790C publication Critical patent/CA2322790C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention concerne de nouveaux composés de granulatimide et des formulations pharmaceutiques de ceux-ci. Les composés de l'invention sont représentés par la formule (I) ou (II). Dans cette formule, F et F' représentent indépendamment R ou Z tels que définis ci-dessous, ou F et F' en combinaison représentent Ar1 tel que défini ci-dessous; Ar1 représente un système monocyclique, bicyclique ou tricyclique partiellement ou totalement aromatique, contenant des noyaux carbocycliques à cinq ou six éléments, ou de l'oxygène, de l'azote ou du soufre comprenant des noyaux hétérocycliques, éventuellement substitués par R ou Z; W est sélectionné dans le groupe constitué par les formules (i), (ii) ou (iii), les structures étant telles que ci-dessous.
CA002322790A 1998-03-13 1999-03-11 Derives de granulatimide utilises dans le traitement du cancer Expired - Fee Related CA2322790C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002322790A CA2322790C (fr) 1998-03-13 1999-03-11 Derives de granulatimide utilises dans le traitement du cancer

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CA 2232074 CA2232074A1 (fr) 1998-03-13 1998-03-13 Composes de granulatimide en tant qu'inhibiteurs du point de contr le g2
CA2,232,074 1998-03-13
CA002245029A CA2245029A1 (fr) 1998-03-13 1998-08-14 Composes granulatimide en tant qu'inhibiteurs de controle g2
CA2,245,029 1998-08-14
US09/258,991 US6291447B1 (en) 1998-03-13 1999-02-26 Granulatimide compounds and uses thereof
US09/258,991 1999-02-26
PCT/CA1999/000224 WO1999047522A1 (fr) 1998-03-13 1999-03-11 Derives de granulatimide utilises dans le traitement du cancer
CA002322790A CA2322790C (fr) 1998-03-13 1999-03-11 Derives de granulatimide utilises dans le traitement du cancer

Publications (2)

Publication Number Publication Date
CA2322790A1 CA2322790A1 (fr) 1999-09-23
CA2322790C true CA2322790C (fr) 2008-06-10

Family

ID=27427427

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002322790A Expired - Fee Related CA2322790C (fr) 1998-03-13 1999-03-11 Derives de granulatimide utilises dans le traitement du cancer

Country Status (1)

Country Link
CA (1) CA2322790C (fr)

Also Published As

Publication number Publication date
CA2322790A1 (fr) 1999-09-23

Similar Documents

Publication Publication Date Title
EP1070068B1 (fr) Derives de granulatimide utilises dans le traitement du cancer
KR100756686B1 (ko) 이성질체 접합 피롤로카르바졸 및 이소인돌론
CA2135768C (fr) Indolocarbazoleimides et mode d'utilisation
Havlicek et al. 8-Azapurines as new inhibitors of cyclin-dependent kinases
JP2002518395A (ja) 縮合アゼピノン型サイクリン依存性キナーゼ阻害物質
US6291447B1 (en) Granulatimide compounds and uses thereof
CN114195814B (zh) 羟基萘酮-苯硼酸类化合物、制备方法和用途
CA2322790C (fr) Derives de granulatimide utilises dans le traitement du cancer
US20040242508A1 (en) Novel hydroxyalkyl indolocarbazole derivatives, preparation method and pharmaceutical compositions containing the same
KR100392468B1 (ko) 사이클린 의존 키나아제의 저해제로서 유용한3-히드록시크로멘-4-온 유도체
EP1252155B1 (fr) Solvate d'ethanol sous forme (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8- [4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one
KR100874209B1 (ko) 3,10-다이하이드로-1Ｈ-[1,4]다이아제피노[5,6-ｂ]인돌-2-온 유도체 및 약학적으로 허용 가능한 염, 그의 제조방법및 그의 용도
KR100399345B1 (ko) 아미노나프토퀴논구조를갖는사이클린-의존키나아제저해제화합물
Marchivie et al. Jean Guillon*, Solène Savrimoutou, Sandra Rubio, Stéphane Moreau, Noël Pinaud 2
CN117800979A (zh) 一类四氢苯并呋喃[2,3-c]吡啶类激酶抑制剂及其制备方法及用途
JP2004515554A (ja) インドロカルバゾール抗癌剤およびそれを使用する方法
CA2232074A1 (fr) Composes de granulatimide en tant qu'inhibiteurs du point de contr le g2

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed